EMERGENT STRATEGIES

Lobbying for GENBIOPRO, INC. · Generic Pharmaceutical Manufacturer

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Nevada · House · Senate · $35,000.00 income · posted Oct 20, 2025

Lobbying activity 3

Pharmacy

FDA Approval of generic mifepristone and relate Risk Evaluation Mitigation Strategies (REMS)

Veterans

VA rule making on providing abortion services to veterans

Health Issues

Issues related to medication abortion; Issues related to abortion access

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.